← Back to Stocks

MRK - Merck & Co., Inc.

Health Care

Price History

About

Industry

Drug Manufacturers - General

Employees

73,000

Headquarters

United States


Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Price

$133.72

52-Week Range

$96 $157

Dividend Yield

2.63%

Dividend Score

C

Dividend

Yield 2.63%
Annual $3.52
Payout 343%
5Y Avg 2.87%

Valuation

P/E (TTM) 135.1
Fwd P/E 14.9
P/B 7.35
PEG 3.24

Profitability

Profit Margin 3.6%
Op Margin 35.2%
ROE 5.1%
ROA 11.3%

Financial Health

Current Ratio 1.35
Quick Ratio 0.81
Debt/Equity 120%

Cash Flow

Free CF $14.0B
Op CF $18.7B
Total Cash $9.6B

Performance (12M)

Price Change +40.80%
Total Return +44.34%

Analyst Consensus

Buy

26 analysts

Target: $162 $105 - $186
+20.8% implied

Annual Return Breakdown

Dividend Growth

Most Recent Annual Growth

5.13%

3-Year Avg Growth

5.42%

5-Year Avg Growth

6.76%

Annual Dividends

Year-over-Year Growth

Recent Dividend History

Ex-Dividend Date Amount
Sep 15, 2026 $0.8500
Jun 15, 2026 $0.8500
Mar 16, 2026 $0.8500
Dec 15, 2025 $0.8500
Sep 15, 2025 $0.8100
Jun 16, 2025 $0.8100
Mar 17, 2025 $0.8100
Dec 16, 2024 $0.8100
Sep 16, 2024 $0.7700
Jun 17, 2024 $0.7700
Mar 14, 2024 $0.7700
Dec 14, 2023 $0.7700
Sep 14, 2023 $0.7300
Jun 14, 2023 $0.7300
Mar 14, 2023 $0.7300
Dec 14, 2022 $0.7300
Sep 14, 2022 $0.6900
Jun 14, 2022 $0.6900
Mar 14, 2022 $0.6900
Dec 14, 2021 $0.6900